These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12451285)

  • 1. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.
    Bruchfeld A; Lindahl K; Schvarcz R; Ståhle L
    Ther Drug Monit; 2002 Dec; 24(6):701-8. PubMed ID: 12451285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function.
    Kamar N; Chatelut E; Manolis E; Lafont T; Izopet J; Rostaing L
    Am J Kidney Dis; 2004 Jan; 43(1):140-6. PubMed ID: 14712437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
    Jain AB; Eghtesad B; Venkataramanan R; Fontes PA; Kashyap R; Dvorchik I; Shakil AO; Kingery L; Fung JJ
    Liver Transpl; 2002 Nov; 8(11):1007-13. PubMed ID: 12424713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.
    Jen JF; Glue P; Gupta S; Zambas D; Hajian G
    Ther Drug Monit; 2000 Oct; 22(5):555-65. PubMed ID: 11034261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C.
    Maeda Y; Kiribayashi Y; Moriya T; Maruhashi A; Omoda K; Funakoshi S; Murakami T; Takano M
    Ther Drug Monit; 2004 Feb; 26(1):9-15. PubMed ID: 14749543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.
    Bruchfeld A; Lindahl K; Ståhle L; Söderberg M; Schvarcz R
    Nephrol Dial Transplant; 2003 Aug; 18(8):1573-80. PubMed ID: 12897097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia.
    Lindahl K; Schvarcz R; Bruchfeld A; Ståhle L
    J Viral Hepat; 2004 Jan; 11(1):84-7. PubMed ID: 14738562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations.
    Slavenburg S; Huntjens-Fleuren HW; Dofferhoff TS; Richter C; Koopmans PP; Verwey-Van Wissen CP; Drenth JP; Burger DM
    Ther Drug Monit; 2011 Feb; 33(1):40-4. PubMed ID: 21191316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
    Kamar N; Guitard J; Ribes D; Esposito L; Rostaing L
    Exp Clin Transplant; 2008 Dec; 6(4):271-5. PubMed ID: 19338488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.
    Maynard M; Pradat P; Gagnieu MC; Souvignet C; Trepo C
    Antivir Ther; 2008; 13(4):607-11. PubMed ID: 18672540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
    Gutierrez-Valencia A; Ruiz-Valderas R; Ben-Marzouk-Hidalgo OJ; Torres-Cornejo A; Espinosa N; Castillo-Ferrando JR; Viciana P; Lopez-Cortes LF
    Antimicrob Agents Chemother; 2015; 59(6):3257-62. PubMed ID: 25801562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.
    Zopf S; Herold C; Hahn EG; Ganslmayer M
    Scand J Gastroenterol; 2009; 44(4):486-90. PubMed ID: 19117241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.
    Gupta SK; Kantesaria B; Glue P
    Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
    Tsubota A; Akuta N; Suzuki F; Suzuki Y; Someya T; Kobayashi M; Arase Y; Saitoh S; Ikeda K; Kumada H
    Intervirology; 2002; 45(1):33-42. PubMed ID: 11937769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
    Burra P; Senzolo M; Masier A; Prestele H; Jones R; Samuel D; Villamil F
    Dig Liver Dis; 2009 May; 41(5):350-6. PubMed ID: 19046932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.
    Tod M; Farcy-Afif M; Stocco J; Boyer N; Bouton V; Sinègre M; Marcellin P
    Clin Pharmacokinet; 2005; 44(4):417-28. PubMed ID: 15828854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.
    Wu LS; Rower JE; Burton JR; Anderson PL; Hammond KP; Baouchi-Mokrane F; Everson GT; Urban TJ; D'Argenio DZ; Kiser JJ
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2179-88. PubMed ID: 25645847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing.
    K Gupta S; Kantesaria B; Glue P
    Drug Discov Ther; 2014 Apr; 8(2):89-95. PubMed ID: 24815584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.